U.S. drug prices are nearly four times higher than the combined average price for 11 other similar countries, according to a report released today by the House Ways and Means Committee. Committee staff analyzed 2018 pricing data for 79 drugs sold in the U.S., United Kingdom, Japan, Canada (Ontario), Australia, Portugal, France, the Netherlands, Germany, Denmark, Sweden and Switzerland. “With one exception, we found that individual drug prices in the U.S. ranged from 70% (Lantus Solostar – a type of insulin) to 4,833% (Dulera – a prescription asthma medication) higher than the combined mean price in the other 11 countries,” the report states. “Compared to individual countries, drug prices in the U.S. ranged from 0.6 to 67 times the price for the same drugs.”

Headline
The Centers for Medicare & Medicaid Services announced in a memo April 21that it is delaying implementation of the Medicare Part D portion of the Better…
Headline
President Trump April 18 signed an executive order to accelerate research into psychedelic drugs for the treatment of serious mental illnesses, calling…
Headline
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…
Headline
The White House April 2 issued a proclamation implementing additional tariffs on certain patented pharmaceutical products and ingredients. The order imposes a…
Headline
The Centers for Medicare & Medicaid Services April 2 released a final rule on policy and technical changes to Medicare Advantage, the Medicare Prescription…
Headline
The AHA commented today on the Centers for Medicare & Medicaid Services’ proposed rule on the Global Benchmark for Efficient Drug Pricing Model, or…